Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Parallel-Controlled, Double-Blind, Double-Dummy, Multicenter, Phase III Clinical Trial of Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)

NCT05594927 is registered in ClinicalTrials.gov with Beijing Shenogen Biomedical Co., Ltd as lead sponsor.

NCT NCT05594927
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05594927 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Parallel-Controlled, Double-Blind, Double-Dummy, Multicenter, Phase III Clinical Trial of Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)
Lead sponsor
Beijing Shenogen Biomedical Co., Ltd
Phase
Phase 3
Overall status
Recruiting
Start date
December 12, 2022
Completion date
August 30, 2025
Enrollment
261 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma